Syngenta's advisers target a valuation of at least $66bn for its Hong Kong listing
Reuters reports UBS and CICC are marketing Syngenta's Hong Kong listing at 15 to 20 times core earnings, implying $66bn to $88bn.
Advisers to Syngenta are targeting a valuation of at least $66bn for the agrochemical and seeds group's planned Hong Kong listing, Reuters reported on 27 October, citing two people familiar with the matter. UBS and China International Capital Corporation are marketing the company at 15 to 20 times expected 2026 core earnings, according to the report. Applied to the group's 2025 EBITDA of $4.4bn, that range implies a valuation of $66bn to $88bn. Syngenta and UBS declined to comment, Reuters said, while CICC, China CITIC Bank and Bank of America did not immediately respond.
The company plans to sell a stake of 10 to 20 percent, which on those figures would raise $5bn to $10bn, with the proceeds going to reduce debt and to fund investment in crop protection products and seeds. Syngenta has already filed for the flotation, having lodged a confidential application in September aiming to raise at least $5bn, as Reuters reported at the time. China CITIC Bank and Bank of America are helping run the offering alongside UBS and CICC. Bankers have been meeting investors in Shanghai, Hong Kong and Beijing, with marketing planned in Frankfurt and London. A debut in early 2027 is considered most likely, although three sources told Reuters it could still happen before the end of 2026. One said: "There's confidence a January window is feasible."
The valuation rests on a business that has been repairing its margins rather than growing its top line. Syngenta Group reported 2025 sales of $28.4bn, down 1 percent, with EBITDA of $4.4bn, up 13 percent, and an EBITDA margin of 15.4 percent, 1.9 percentage points higher than the previous year. Within that, Syngenta Crop Protection posted sales of $13.7bn, up 4 percent, and Syngenta Seeds $4.8bn, up 2 percent. The group employs more than 50,000 people in over 90 countries. It is controlled by the Chinese state owned Sinochem, which bought it for $43bn in 2017, and it recently appointed Hengde Qin as chief executive. A proposed Shanghai listing was withdrawn in 2024.
According to the Reuters sources, Syngenta is being presented to investors as a biotechnology company rather than a chemicals producer, with the argument built on its crop protection range and a seed pipeline of varieties resistant to disease and pests. The timing is being read against a strong Hong Kong market: 118 new listings raised HK$388.0bn, about $49.5bn, in the first nine months of 2026, more than double the same period a year earlier. Sentiment has cooled this month after a selloff in artificial intelligence stocks, and two other Chinese companies postponed offerings, which is one reason bankers are keeping the early 2027 option open.
Why it matters for AgTech founders: a listing of this size resets the reference price for everything underneath it. Three things follow. First, the multiple matters more than the headline number. Fifteen to twenty times core earnings for one of the largest crop input businesses in the world is the public comparable that growth investors will hold against your plan, and a biologicals or seed trait company asking for a revenue multiple far above that needs a prepared answer for why the gap is justified. Second, read the positioning. The company is being marketed as biotechnology rather than chemistry, which is a deliberate decision about which pipeline the market is asked to pay for. That choice is available to you at seed stage, and it is far cheaper to make early than to retrofit before a Series B. Third, a company inside a listing window behaves differently as a counterparty. Partnering and licensing decisions slow down, diligence gets stricter, and anything that might complicate a prospectus tends to wait. If Syngenta sits on your target list for a trial, a distribution agreement or an exit, plan for a quiet period running into early 2027 and build the alternatives now.
Syngenta's advisers target a valuation of at least $66bn for its Hong Kong listing
UBS and CICC are marketing the Basel group at 15 to 20 times expected 2026 core earnings. A sale of 10 to 20 percent could raise $5bn to $10bn, with the listing most likely in early 2027.
Advisers to Syngenta are targeting a valuation of at least $66bn for the agrochemical and seeds group's planned Hong Kong listing, Reuters reported on 27 October, citing two people familiar with the matter. UBS and China International Capital Corporation are marketing the company at 15 to 20 times expected 2026 core earnings, according to the report. Applied to the group's 2025 EBITDA of $4.4bn, that range implies a valuation of $66bn to $88bn. Syngenta and UBS declined to comment, Reuters said, while CICC, China CITIC Bank and Bank of America did not immediately respond.
The company plans to sell a stake of 10 to 20 percent, which on those figures would raise $5bn to $10bn, with the proceeds going to reduce debt and to fund investment in crop protection products and seeds. Syngenta has already filed for the flotation, having lodged a confidential application in September aiming to raise at least $5bn, as Reuters reported at the time. China CITIC Bank and Bank of America are helping run the offering alongside UBS and CICC. Bankers have been meeting investors in Shanghai, Hong Kong and Beijing, with marketing planned in Frankfurt and London. A debut in early 2027 is considered most likely, although three sources told Reuters it could still happen before the end of 2026. One said: "There's confidence a January window is feasible."
The valuation rests on a business that has been repairing its margins rather than growing its top line. Syngenta Group reported 2025 sales of $28.4bn, down 1 percent, with EBITDA of $4.4bn, up 13 percent, and an EBITDA margin of 15.4 percent, 1.9 percentage points higher than the previous year. Within that, Syngenta Crop Protection posted sales of $13.7bn, up 4 percent, and Syngenta Seeds $4.8bn, up 2 percent. The group employs more than 50,000 people in over 90 countries. It is controlled by the Chinese state owned Sinochem, which bought it for $43bn in 2017, and it recently appointed Hengde Qin as chief executive. A proposed Shanghai listing was withdrawn in 2024.
According to the Reuters sources, Syngenta is being presented to investors as a biotechnology company rather than a chemicals producer, with the argument built on its crop protection range and a seed pipeline of varieties resistant to disease and pests. The timing is being read against a strong Hong Kong market: 118 new listings raised HK$388.0bn, about $49.5bn, in the first nine months of 2026, more than double the same period a year earlier. Sentiment has cooled this month after a selloff in artificial intelligence stocks, and two other Chinese companies postponed offerings, which is one reason bankers are keeping the early 2027 option open.
Why it matters for AgTech founders: a listing of this size resets the reference price for everything underneath it. Three things follow. First, the multiple matters more than the headline number. Fifteen to twenty times core earnings for one of the largest crop input businesses in the world is the public comparable that growth investors will hold against your plan, and a biologicals or seed trait company asking for a revenue multiple far above that needs a prepared answer for why the gap is justified. Second, read the positioning. The company is being marketed as biotechnology rather than chemistry, which is a deliberate decision about which pipeline the market is asked to pay for. That choice is available to you at seed stage, and it is far cheaper to make early than to retrofit before a Series B. Third, a company inside a listing window behaves differently as a counterparty. Partnering and licensing decisions slow down, diligence gets stricter, and anything that might complicate a prospectus tends to wait. If Syngenta sits on your target list for a trial, a distribution agreement or an exit, plan for a quiet period running into early 2027 and build the alternatives now.
